RxSight Non-GAAP EPS of -$0.13 beats by $0.14, revenue of $28.6M beats by $0.74M (NASDAQ:RXST)

The company is reiterating guidance for full-year 2024 revenue, gross profit margin, and operating expenses:

• Revenue guidance range of $128.0 million to $135.0 million, representing implied growth of 44% to 52% compared to 2023.
• Gross margin guidance range of 65% to 67%, representing an implied increase of 500 bps to 700 bps compared to 2023.
• Operating expense guidance range of $125.0 million to $128.0 million, representing an implied growth of 20% to 23% compared to 2023, and including non-cash expense guidance in the range of $22.0 million to $25.0 million.